- MOHAP clinical trial approval is required for all Phase I–IV trials conducted in the UAE
- Dubai Health Authority (DHA) ethics committee approval is required for Dubai trial sites
- ADPHC (Abu Dhabi Public Health Centre) approval required for Abu Dhabi trial sites
- ICH-GCP (Good Clinical Practice) compliance is mandatory for all UAE clinical trials
- UAE CRO market is growing at 12% per year driven by Gulf pharma expansion
- The UAE has 50+ JCI-accredited hospitals qualifying as international-standard trial sites
- Phase I–III trial budgets typically range from AED 500,000 to AED 2,000,000 per study
- UAE’s central GCC location gives access to a Gulf patient pool of 60+ million people
Introduction: UAE Clinical Research Organization (CRO) Sector — Updated August 2026
The United Arab Emirates has emerged as the Middle East’s premier destination for clinical research and pharmaceutical trials. The combination of world-class JCI-accredited hospitals, a diverse and ethnically varied patient population, a progressive regulatory environment led by the UAE Ministry of Health and Prevention (MOHAP), and strategic proximity to the Gulf Cooperation Council (GCC) market of 60+ million people makes the UAE a compelling location for pharmaceutical companies, biotech firms, and clinical research organizations (CROs) seeking to conduct high-quality clinical trials.
The UAE CRO market is growing at approximately 12% per year, fuelled by increasing pharmaceutical investment in the MENA region, the post-COVID-19 acceleration in clinical research outsourcing, and the UAE government’s broader Healthcare Sector Strategy 2023–2026 which explicitly targets making the UAE a hub for healthcare innovation and clinical research.
This comprehensive guide covers the regulatory approvals required to establish and operate a Clinical Research Organization (CRO) in the UAE in 2026, including MOHAP clinical trial approval processes, DHA and ADPHC ethics committee requirements, ICH-GCP compliance obligations, and the practical steps to set up a CRO operation.
What Is a Clinical Research Organization (CRO)?
A Clinical Research Organization (CRO) is a contract service provider to the pharmaceutical, biotechnology, and medical device industries. CROs provide a spectrum of research services including study design, patient recruitment, site management, data management, biostatistics, regulatory affairs support, and pharmacovigilance — enabling pharmaceutical sponsors to outsource part or all of the clinical development process.
In the UAE context, CROs typically provide services in two models:
- Full-service CRO — manages the entire clinical trial from protocol design to final study report on behalf of the sponsor
- Functional Service Provider (FSP) — provides specific functions (e.g., data management only, or patient recruitment only) embedded within the sponsor’s own team
A related but distinct entity is the Site Management Organization (SMO), which does not run trials itself but manages the operational aspects of trial sites (hospitals, clinics), including regulatory submissions, patient informed consent, and trial master file maintenance. SMOs are growing rapidly in the UAE as hospitals seek professional support for their increasing trial portfolios.
UAE Clinical Trial Regulatory Framework
Clinical trials in the UAE are regulated across several tiers of authority, with jurisdiction depending on the emirate where the trial is conducted and the type of intervention:
| Authority | Jurisdiction | Approval Required |
|---|---|---|
| MOHAP (Ministry of Health & Prevention) | Federal (all UAE) | Mandatory for all Phase I–IV interventional trials |
| DHA Ethics Committee | Dubai emirate | Required for any trial site in Dubai (DHA-licensed facilities) |
| ADPHC Research Committee | Abu Dhabi emirate | Required for all Abu Dhabi trial sites |
| SEHA / HAAD | Abu Dhabi (legacy) | Site-specific institutional review board (IRB) |
| MOHAP Import Permit (IMP) | Federal | For import of Investigational Medicinal Products |
| UAE Data Office / TDRA | Federal | For transfer of patient health data out of UAE |
MOHAP Clinical Trial Approval: The Federal Process
The MOHAP clinical trial approval is the cornerstone regulatory requirement for any clinical trial conducted in the UAE, regardless of the phase or emirate. MOHAP’s Drug Department manages the trial approval process through its clinical trials unit. The process involves:
- Pre-submission meeting — optional but strongly recommended; MOHAP’s clinical trials office provides guidance on protocol requirements
- Document package submission — protocol, investigator brochure, informed consent template, ethical opinion (from relevant ethics committee), insurance certificate, and sponsor authorization letter
- Scientific review — MOHAP’s review committee assesses protocol scientific merit, patient safety safeguards, and UAE-specific regulatory compliance
- Approval or requests for additional information — MOHAP typically responds within 45–90 days; additional information requests are common and can extend the timeline
- Investigational Medicinal Product (IMP) import permit — issued separately for each shipment of trial drug to UAE sites
All clinical trial applications to MOHAP must be submitted in English. Arabic translations of patient-facing documents (informed consent, patient information sheets) are mandatory.
ICH-GCP Compliance: The International Standard
ICH-GCP (International Council for Harmonisation — Good Clinical Practice) is the internationally recognised standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. All clinical trials conducted in the UAE must comply with ICH-GCP E6(R2), the current revision that emphasises risk-based monitoring and electronic systems.
Key ICH-GCP requirements relevant to UAE CROs:
- Qualified Principal Investigator (PI) — each trial site must have a qualified medical professional as the responsible PI
- Trial Master File (TMF) — comprehensive documentation must be maintained electronically or in paper form at both the sponsor and site levels
- Risk-Based Monitoring (RBM) — E6(R2) emphasises risk proportionate monitoring rather than 100% source data verification
- Electronic data capture (EDC) — validated eCRF systems (Medidata Rave, Oracle Clinical, REDCap) are expected for all Phase II–IV trials
- Pharmacovigilance — Serious Adverse Events (SAEs) must be reported to MOHAP within 7 days (fatal/life-threatening) or 15 days (other serious events)
UAE Trial Site Infrastructure: 50+ JCI-Accredited Hospitals
The UAE’s clinical research infrastructure has expanded dramatically over the past decade. As of 2026, the UAE has over 50 hospitals accredited by the Joint Commission International (JCI) — the gold standard for international hospital quality that ensures trial sites meet the quality and safety standards required by global pharmaceutical sponsors.
Key UAE trial sites include:
- Cleveland Clinic Abu Dhabi — flagship tertiary care facility with established research department
- American Hospital Dubai — longstanding oncology and cardiology trial experience
- Mediclinic City Hospital (Dubai Healthcare City) — within the DHCC regulated zone, specialist research protocols
- Sheikh Khalifa Medical City (Abu Dhabi) — large government hospital with ADPHC research governance
- Dubai Hospital (DHA) — government facility with ethics committee infrastructure
CRO License Type & Cost Structure
| Cost Item | Estimated Cost (AED) | Notes |
|---|---|---|
| DED / DHCC Management License | AED 15,000–30,000/yr | Healthcare consulting/CRO activities |
| MOHAP Establishment License (if clinical) | AED 10,000–25,000/yr | For SMO operating within clinical settings |
| Company Incorporation | AED 10,000–20,000 | One-time cost |
| Office Lease (Dubai Healthcare City preferred) | AED 60,000–150,000/yr | DHCC location preferred for pharma clients |
| Trial Approval Fees (per study, MOHAP) | AED 5,000–15,000 | Government fee per trial application |
| Phase I–III Study Budget (per study) | AED 500,000–2,000,000 | Patient recruitment, site fees, data management |
Dubai Healthcare City (DHCC): The Preferred CRO Hub
Dubai Healthcare City is a free zone specifically designed for healthcare and life sciences businesses. Operating from DHCC provides CROs and SMOs with several advantages:
- Proximity to trial sites (Mediclinic City Hospital is within DHCC)
- DHCC Authority licensing with healthcare-specific regulatory understanding
- Cluster of pharma companies, medical device firms, and healthcare consultancies providing business development opportunities
- DHA oversight infrastructure aligned with clinical research compliance
- 100% foreign ownership and 0% corporate tax on qualifying income
Frequently Asked Questions
Q1: Does a CRO need a specific healthcare license or is a standard business license sufficient?
It depends on the CRO’s scope of activities. A CRO providing purely consulting, data management, statistics, or regulatory writing services does not conduct clinical activities and can operate under a standard DED or freezone management consultancy license. However, if the CRO directly employs clinical staff (nurses, coordinators) who interact with trial patients in clinical settings, a MOHAP healthcare establishment license or DHA facility license may be required. SMOs almost always require healthcare establishment licensing. We recommend consulting MOHAP’s licensing office early in the setup process.
Q2: How long does MOHAP clinical trial approval take?
The MOHAP clinical trial approval process typically takes 45–90 days from submission of a complete application package. Incomplete submissions or protocols requiring significant scientific revision can extend this to 6+ months. Running the ethics committee approval (DHA or ADPHC) in parallel with the MOHAP review can reduce the overall timeline, as both approvals are needed before a trial can start. Experienced UAE CROs recommend allowing 4–6 months from first submission to site activation.
Q3: Can Phase I first-in-human trials be conducted in the UAE?
Yes, Phase I trials (including first-in-human studies) can be conducted in the UAE, subject to MOHAP approval and the availability of an appropriately equipped Phase I unit. As of 2026, dedicated Phase I units exist within a small number of UAE hospitals (primarily in Abu Dhabi and Dubai). MOHAP reviews Phase I applications with particular rigour, and the sponsor may be required to present additional pharmacological and toxicological data compared to regulatory submissions in the EU or US.
Q4: Are there data residency requirements for clinical trial data in the UAE?
The UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and the UAE Data Office guidelines impose requirements on the cross-border transfer of personal health data. For clinical trial data that is linked to patient identifiers, sponsors and CROs must ensure appropriate data transfer mechanisms are in place before sending UAE patient data to non-UAE servers or sponsor headquarters. Pseudonymisation, standard contractual clauses, or adequacy determinations from the UAE Data Office are the available mechanisms. Sponsors from countries with bilateral data adequacy frameworks have a streamlined process.
Q5: What are the patient recruitment challenges unique to the UAE?
The UAE’s unique demographic composition — over 200 nationalities, ~90% expatriate population with high mobility — presents specific patient recruitment challenges. Patients may leave the UAE mid-trial (employment contract ending, family relocation), creating high screen failure and drop-out rates in long-duration studies. Patient retention strategies must account for expatriate mobility patterns. On the positive side, the UAE’s multicultural population provides access to genetically and ethnically diverse patient cohorts that are increasingly valued for global trials seeking diverse population data. For therapeutic areas where South Asian or Arab patient populations are specifically needed, the UAE offers excellent access.